Article

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination

2022-09-21

Abstract excerpt

Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rate (RR) following SARS-CoV-2 vaccination. To investigate the relationship between the initial transcriptional response to vaccination with ensuing B and T cell immune responses, we performed a comprehensive immune transcriptome analysis flanked by antibody and T cell assay...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f73afe20-8d39-5f11-94aa-76c1389ba7d0
DOI: 10.1101/2022.09.21.22280205

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccinationDOI 10.1101/2022.09.21.22280205Read

SARS-CoV-2 vaccination unmasks distinct immune dysfunctions across lymphoma subtypes and therapiesSemantic proximity Read

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineSemantic proximity Read

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsSemantic proximity Read

Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus InfectionSemantic proximity Read

Antibody Responses After First and Second COVID-19 Vaccination in Patients With Chronic Lymphocytic LeukaemiaSemantic proximity Read

mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infectionSemantic proximity Read

COVID-19 Vaccine Failure in Chronic Lymphocytic Leukemia and Monoclonal B-Lymphocytosis; Humoral and Cellular ImmunitySemantic proximity Read

Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancerSemantic proximity Read

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patientsSemantic proximity Read

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialSemantic proximity Read

mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infectionSemantic proximity Read

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity Read